uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted November 24, 2018

Dangerous Drug In Supplements for Pain and Anxiety

On November 20, 2018, the FDA announced it has issued warning letters to two companies for the illegal marketing of products labeled as dietary supplements that contain the opioid-like drug tianeptine. Use the links below to see the FDA's warning letter for each product:
  • Tianaa Red, Tianaa White, and Tianaa Green, sold by Jack B Goods Outlet Store, are labeled as containing tianeptine sodium. The products are promoted with statements such "It has been our experience that there is a natural reaction that affects the serotonin receptor site providing an unparalleled solution to cravings for opiates," and "There has never been such a clear choice for pain and anxiety."

  • Vicaine, sold by MA Labs LLC, is also labeled as containing tianeptine sodium. It is promoted with claims such as "Produces both stimulatory and opiate-like effects," "[P]ain-killer, ... euphoriant, speed-ball in a bottle, stress-reducing agent..." and "Lastly, tianeptine tends to balance out the stimulant half of the product by alleviating any anxiety or restlessness that may transpire through stimulant use."
Tianeptine is an atypical tricyclic drug used as an antidepressant in Europe, Asia, and Latin America. In the U.S., however, the drug is not approved for medical use and is an unscheduled pharmaceutical agent. Tianeptine can cause effects similar to opioids, and misuse can lead to severe neurologic, cardiovascular, and gastrointestinal symptoms, and opioid-like dependence and overdose. Stopping the drug can cause withdrawal symptoms similar to those experienced when stopping opioid drugs, such as agitation, sweating, nausea, vomiting, rapid heartbeat, high blood pressure and tremor. The Center for Disease Control (CDC) has reported an increase in tianeptine exposure calls to U.S. poison control centers during from 2014 to 2017.

To read the FDA's complete news release, use the link below.